ClinicalTrials.gg
Not yet recruitingNCT06537167Updated May 15, 2025

Transcutaneous Electrical Acupoint Stimulation on Blood Pressure

An interventional study of Transcutaneous electrical acupoint stimulation and Sham stimulation in Hypertension, sponsored by Shanghai Jiao Tong University School of Medicine. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-15.

Sponsored by Shanghai Jiao Tong University School of Medicine · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Hypertension by Shanghai Jiao Tong University School of Medicine — 6 open to participants now, 7 under way, none of them phase 3. Hypertension · Shanghai Jiao Tong University School of Medicine.

Planned enrollment
10th of 13
120 · median 320
Started
2025
with 1 other
No phase
4 of 15
3 open now
Registered
13th of 15
by date

Among the 15 studies in Hypertension by Shanghai Jiao Tong University School of Medicine, this one is the 10th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2025, is one of 4 with no phase, and was the 13th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 15 studies in Hypertension by Shanghai Jiao Tong University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hypertension by Shanghai Jiao Tong University School of Medicine, or all of them as a file.
02

Study summary

This study will be conducted in patients with high-normal blood pressure and grade 1 hypertension and will be divided into two phases.

In Phase One, a small group of patients will undergo transcutaneous electrical acupoint stimulation treatment for three consecutive days. Blood pressure changes will be observed before and after each stimulation session, as well as 1 hour, 3 hours, and 5 hours after stimulation, during the night of the treatment day, and the next morning.

Phase Two will be a single-center, single-blind, parallel randomized controlled trial. After screening, patients will be randomly assigned to either the "stimulation" experimental group or the "sham stimulation" control group. For three consecutive days, both groups will receive their respective interventions at the same time each day, and their blood pressure changes will be recorded.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Office systolic blood pressure between 130-150 mmHg and/or diastolic blood pressure between 80-95 mmHg
  • Age between 18 and 75 years
  • Not currently receiving antihypertensive medication or having discontinued antihypertensive medication for more than two weeks
  • Able to undergo and complete the transcutaneous electrical acupoint stimulation treatment
  • Agree to participate and sign the form

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding women
  • Severe heart conditions, including coronary heart disease, myocardial infarction, arrhythmia, heart failure, or having an implanted cardiac pacemaker
  • Skin conditions, including eczema, allergic dermatitis, or seborrheic dermatitis
  • Neuromuscular diseases, mental disorders, epilepsy, or cognitive impairment
  • Lower limb deep vein thrombosis or thrombophlebitis
  • Wounds, surgical scars, or malignant tumors at the stimulation areas
  • Inability to tolerate the transcutaneous electrical acupoint stimulation treatment or allergic to electrical stimulation
  • Currently participating in other clinical trials
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    "Stimulation" Experimental Group

    Device: Transcutaneous electrical acupoint stimulation

  • Sham comparator
    "Sham Stimulation" Control Group

    Device: Sham stimulation

Interventions

  • DeviceTranscutaneous electrical acupoint stimulation

    Participants will receive proper transcutaneous electrical acupoint stimulation treatment for three consecutive days. Each day, the selected five target acupoints (Renying, Quchi, Taichong, Zusanli, and Hegu) will be stimulated in rotation. Each acupoint will be stimulated once a day for 10 minutes, with a 2-minute interval between each acupoint, totaling 60 minutes. Throughout the trial, the stimulation parameters for each participant will remain constant, and the treatment will begin between 8:00 and 10:00 AM each day.

  • DeviceSham stimulation

    Participants will receive sham stimulation treatment, where the left-side skin near the selected five target acupoints (avoiding other functional acupoints) will be stimulated in rotation. The stimulation time and method will be the same as in the experimental group. Throughout the trial, the stimulation parameters for each participant will remain constant, and the treatment will begin between 8:00 and 10:00 AM each day.

06

What researchers measure

Primary outcomes

  1. Change in office systolic blood pressure between the third day after TEAS treatment and the baseline (before the start of treatment on the first day)

    Time frame: At the third day after TEAS treatment and the baseline (before the start of treatment on the first day)

Secondary outcomes

  1. Changes in office systolic blood pressure at other time points before and after treatment

    Time frame: At all other time points (excluding the third day after treatment) and the baseline (before the start of treatment on the first day)

  2. Changes in office diastolic blood pressure at various time points before and after treatment

    Time frame: At each time point before and after treatment and the baseline (before the start of treatment on the first day).

  3. Changes in ambulatory blood pressure before and after treatment

    Time frame: At the third day after the end of treatment and the baseline (before the start of treatment on the first day)

  4. Changes in Hamilton Scale scores before and after treatment

    Time frame: At the third day after the end of treatment and the baseline (before the start of treatment on the first day)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Dec 2027, 28 months later.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 28 months is above that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2024
First posted
Aug 5, 2024
StartEst.
Aug 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
May 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06537167
Collaborators
Shanghai Institute of Hypertension, Shanghai Jiao Tong University School of Biomedical engineering
Responsible party
Ji-Guang Wang (Professor of the Shanghai Institute of Hypertension and the Department of Hypertension, Shanghai Jiao Tong University School of Medicine) — Principal investigator
First posted
Aug 5, 2024
Start date
Aug 2025 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
May 15, 2025

Study contacts

Jiguang Wang, MD, PhD
Contact
jiguangwang@rjh.com.cn
021-64370045 ext. 610911

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion